Published in final edited form as:

Arch Surg. 1994 May ; 129(5): 528–533.

Liver Transplantation Without the Use of Blood Products

Hector C. Ramos, MD, Satoru Todo, MD, Yoogoo Kang, MD, Evangelos Felekouras, MD, Howard R. Doyle, MD, and Thomas E. Starzl, MD

Departments of Surgery (Drs Ramos, Todo, Felekouras, Doyle, and Starzl) and Anesthesiology/Critical Care Medicine (Dr Kang), Pittsburgh Transplantation Institute, University of Pittsburgh (Pa) School of Medicine

Abstract

Objectives—To examine the techniques and the outcome of liver transplantation with maximal conservation of blood products and to analyze the potential benefits or drawbacks of blood conservation and salvage techniques.

Design—Case series survey.

Setting—Tertiary care, major university teaching hospital.

Patients and Methods—Four patients with religious objections to blood transfusions who were selected on the basis of restrictive criteria that would lower their risk for fatal hemorrhage, including coagulopathy, a thrombosed splanchnic venous system requiring extensive reconstruction, active bleeding, and associated medical complications. All patients were pretreated with erythropoietin to increase production of red blood cells. All operations were performed at the same institution, with a 36-month follow-up.

Interventions—Orthotopic liver transplantation that used blood salvage, plateletpheresis, and autotransfusion and the withholding of the use of human blood products with the exception of albumin.

Main Outcome Measures—Survival and postoperative complications, with the effectiveness of erythropoietin and plateletpheresis as secondary measures.

Results—All patients are alive at 36 months after orthotopic liver transplantation. One patient, a minor (13 years of age), was transfused per a state court ruling. Erythropoietin increased the production of red blood cells as shown by a mean increase in hematocrit levels of 0.08. Plateletpheresis allowed autologous, platelet-rich plasma to be available for use after allograft reperfusion. Three major complications were resolved or corrected without sequelae. Only one patient developed postoperative hemorrhage, which was corrected surgically. The mean charge for bloodless surgery was \$174 000 for the three patients with United Network for Organ Sharing (UNOS) status 3 priority for transplantation. This result was statistically significant when these patients were compared with all the patients with UNOS status 3 priority during the same period who met the same restrictive guidelines ($P<.05$). Only 19 of 1009 orthotopic liver transplantations performed at our institution were similar according to the UNOS status and the fulfillment of the guidelines. The mean charge for these comparison patients was \$327 000, 3.8% of which was related to transfusions.

Conclusions—Orthotopic liver transplantation without the use of blood products is possible. Blood conservation techniques do not increase morbidity or mortality and can result in fewer transfusion-related, in-hospital charges.

Since first performed by one of us (T.E.S.) in 1963, human liver transplantation has been among the most difficult of operations. One of the factors influencing the outcome of this operation is the amount of blood and blood products required. The operation has required a mean of 10 U of whole blood or packed red blood cells,¹ but at times up to 300 U have been used. Most centers have found this amount of blood extremely taxing on their blood bank supplies. Therefore, liver transplantation should be a fertile field for the study of blood conservation techniques. However, the advances with blood conservation in other major surgical procedures, such as the coronary artery bypass operation and other open-heart procedures, have not been transferred to the domain of liver transplantation.²⁻⁴ Several studies have addressed this issue, with varied results,⁵⁻⁸ but a comprehensive effort to perform liver transplantations without blood products is not reported in the literature. This situation has led to the exclusion of patients with personal, religious, or scientific objections to transfusion from possible liver transplantation. We present the experience of the University of Pittsburgh (Pa) Medical Center with several blood conservation techniques in four patients who were Jehovah's Witnesses, three of whom underwent liver transplantation without the use of blood products.

PATIENTS AND METHODS

PATIENT POPULATION

From October 1990 to July 1993, 1009 transplantations in adult patients were performed at the University of Pittsburgh Medical Center. During this period, four patients who were Jehovah's Witnesses underwent liver transplantation under a specific protocol geared to perform a successful, bloodless procedure. Characteristics of the four patients are shown in Table 1.

PATIENT SELECTION

All patients were selected and their conditions evaluated by a team consisting of two transplantation surgeons, two anesthesiologists, and a legal representative for the institution. Restrictive guidelines for the bloodless surgery protocol were (1) hematocrit level of 0.35 or less after erythropoietin therapy; (2) platelet count of less than $100\,000 \times 10^9/L$; (3) prothrombin time of more than 15.0 seconds; (4) known splanchnic venous anatomy that would require extensive vascular reconstruction at the time of transplantation; (5) active bleeding; and (6) renal failure and other major organ dysfunction. Drugs that may inhibit platelet function or coagulation were strictly withheld.

After selection, a meeting was held with the surgical team, family members, religious counsel, and the anesthesiology staff. Treatment options, the patient's type and severity of liver disease, and the details of the risks and the benefits of transplantation, including the possibility of death, were explained. Acceptable blood volume expanders were discussed with the aid of the patient's religious counsel. In all cases, the use of albumin, plateletpheresis, and cell salvage with autotransfusion were acceptable.

PRETRANSPLANTATION MANAGEMENT

The patients were listed for orthotopic liver transplantation by priority status, according to guidelines of the United Network for Organ Sharing (UNOS).⁹ Each patient started therapy consisting of recombinant erythropoietin, 50 to 100 U/kg subcutaneously three times a week, and ferrous sulfate Fe 59,325 mg orally three times a day, to increase production of

red blood cells.¹⁰⁻¹¹ Phytonadione therapy, 20 mg subcutaneously, was also started to augment coagulation. All blood tests were kept to a minimum, ie, blood was drawn twice in 6 weeks in pediatric vials, using 1 mL of whole blood for routine laboratory evaluations of hematologic, chemistry, and coagulation status.

INTRAOPERATIVE MANAGEMENT AND OPERATIVE TECHNIQUE

Cold ischemia was kept to a minimum. Only local donors were used. The operating room was kept warm to avoid hypothermia and resultant coagulopathy.¹²

All intraoperative blood sampling was also kept to a minimum. Laboratory evaluations included testing for arterial blood gas, electrolyte, and hematocrit levels and thromboelastography. The thromboelastograph (Haemoscope, Hellige, Germany) was used as the primary monitor of coagulation status.¹³ Plateletpheresis was performed after induction by phlebotomizing 5 to 7 L of blood at a flow rate of 60 mL/min and processing through the plateletpheresis unit (Hemonetics, Braintree, Mass).¹⁴ We estimated that one pheresis product of 250 to 300 mL contained a platelet count of $3 \times 10^9/L$ to $8 \times 10^9/L$, to be infused after reperfusion.

Filling pressures were optimized during the pheresis procedure with albumin, crystalloid solutions, and hydroxyethyl starch. Isovolemic hemodilution was therefore achieved in conjunction with the phlebotomy for the plateletpheresis.¹⁵ Phlebotomized, platelet-poor blood was reinfused slowly to maintain oxygen-carrying capacity.

All incisions were made using electrocautery with a coagulation mode. The use of laparotomy sponges was kept to a minimum to allow for the collection of as many red blood cells as possible before stable clots could form. When used, the sponges were drained into the field, and the drained blood was collected with the cell-saver suction. The cell saver 4 (Hemonetics) and the Rapid Infusion System (Hemonetics) were used for the salvage of red blood cells.¹⁶

The native liver was removed in all patients, with the piggyback technique used in three patients to avoid dissection of the retroperitoneal and retrocaval areas.¹⁷ An argon beam coagulator (Birtcher, Irvine, Calif) was used liberally to cauterize raw surfaces. Venovenous bypass, either portal, systemic, or combined, was used in all cases.

On reperfusion of the liver and termination of the venovenous bypass, platelet-rich plasma was slowly returned to the patient. The blood from the venovenous bypass tubing was drained directly into the patient. This process returned between 200 and 250 mL of blood per patient.

All anastomoses were performed in standard fashion. Extra care was taken to use smaller than usual sutures and smaller spacing to minimize bleeding from the anastomotic sites. Jackson Pratt drains were left as monitors for bleeding. These drains proved useful in identifying postoperative bleeding in one patient.

Immunosuppression was induced intraoperatively with tacrolimus (Prograf), 0.05 mg/kg over 24 hours in a continuous intravenous infusion, and methylprednisolone, 1 g. Maintenance corticosteroid therapy consisted of 20 mg of methylprednisolone every 24 hours. An intravenous infusion of tacrolimus, 0.05 mg/kg, was continued until gastrointestinal function returned.

In the immediate postoperative period, hemodynamic monitoring and fluid management were performed in the standard way. All blood drawing was limited. Coagulation was

monitored by thromboelastography, prothrombin time, and platelet count. Any fibrinolysis was corrected with ϵ -aminocaproic acid.¹⁸

Minimal blood drawing guidelines were observed throughout the hospital stay. All patients again received erythropoietin and ferrous sulfate Fe 59 until their hematocrit levels rose to more than 0.35.

STATISTICAL COMPARISON

Of the 1009 patients undergoing transplantation during the study period, 445 were adults with UNOS status 3 priority.⁹ We reviewed the charts of these 445 patients, searching for patients who fulfilled our restrictive guidelines. Only 19 of these patients met our guidelines. All 19 patients underwent transfusion. The in-hospital charges and the charges for the use of blood products for all these patients were compared with the charges of the corresponding group of Jehovah's Witnesses who underwent transplantation. The Mann-Whitney *U* test was used for the statistical comparison of these charges.

RESULTS

All of our patients survived the operation and are alive at present. The mean follow-up period was 36 months.

Three of the patients had UNOS status 3 priority, and one, with a diagnosis of fulminant hepatic failure, had UNOS status 4 priority at the time of transplantation. All had significant indications for urgent liver transplantation (Table 1).¹⁹

The patient with fulminant hepatic failure (patient 4) a 13-year-old boy with a prothrombin time of 21.0 seconds and a platelet count of $93\,000 \times 10^9/L$, received 2 U of packed red blood cells during the transplantation. Blood transfusion in this patient was agreed to preoperatively per a state court ruling. He required reoperation for bleeding 24 hours postoperatively but did not undergo transfusion at that time.

One patient developed posttransplantation pulmonary edema, which later resolved with diuresis. Another patient sustained several episodes of hypotension during the operation. The electrocardiographic findings were consistent with a subendocardial-myocardial infarction and atrial fibrillation. Both problems responded to treatment without sequelae.

The results of preoperative erythropoietin therapy and plateletpheresis are illustrated in Table 2. Only three of the patients received the erythropoietin for 4 weeks or longer, with a resultant mean increase in the hematocrit level of 0.08. Patient 4 sustained a progressive decrease in hematocrit level, despite erythropoietin therapy, and plateletpheresis was not used due to a low initial platelet count.

Estimates of operative blood loss from inspection, recovery of red blood cells in the cell savers, and sponge weighing were approximately 250 mL for patient 1, approximately 700 mL for patient 2, and approximately 750 mL for patients 3 and 4. The mean amount of recovered and reinfused red blood cells, not including the phlebotomized blood for plateletpheresis, was less than 200 mL in all patients. Patient 1 had no transfusable blood recovered, owing to a small amount of surgical bleeding. The in-hospital charges of the study patients with UNOS status 3 priority were compared statistically with the charges of the 19 comparison patients. The difference between the total in-hospital charges was statistically significant ($P < .05$). The mean amount of blood products transfused for the comparison group was 8.82 U of packed red blood cells, 7.95 U of fresh frozen plasma, and 6 U of platelet concentrates. The comparison patients generated 3.8% of their total charges

from the blood bank and the blood products. The charges for erythropoietin therapy and plateletpheresis were approximately \$3000 for each patient, but none exceeded this amount. The charges for erythropoietin therapy alone were \$1500 per patient.

COMMENT

No other surgical endeavor requires as much attention to and expertise with blood conservation techniques as major surgical procedures performed on Jehovah's Witnesses. Our report illustrates that excellent survival for liver transplantation can be achieved in these patients. The idea of performing a liver transplantation without blood is deemed so uncommon and dangerous that all patients with religious or even scientific objections to blood transfusion have not been considered for liver transplantation. However, the techniques for performing this procedure are available to us, and we have shown that, with our stepwise, multidisciplinary approach, this procedure is possible.

The problem presented to us was twofold. One aspect was ethical: Jehovah's Witnesses believe that the life force is contained in the blood. This belief has a specific scriptural basis.^{20–23} and their belief is protected by legal precedent.^{24,25} Therefore, we as physicians cannot transfuse an adult Jehovah's Witness without his or her consent. Parting from that premise, performing a liver transplantation without blood products and with the least amount of danger to the patient was our second major issue. It was clear to us in the beginning that the establishment of informed consent was of prime importance. This principle required us to obtain a state court ruling for patient 4, the minor child of Jehovah's Witness parents, who was in dire need of a liver transplant. The ruling allowed us to do our best to save the child's life, including the use of blood transfusions. Nevertheless, all techniques for blood conservation were used just as with the other three patients, whose operations were done without the safety net of a blood transfusion.

The restrictive guidelines were developed to identify surgical risks for exsanguination. In fact, we have evaluated the cases of 12 patients previously and continue to evaluate cases for this procedure. Two of these patients have died of variceal hemorrhage; eight other cases are at various stages of evaluation.

Preoperative conditioning was of the utmost importance. Patients with liver disease and resultant anemia, from either chronic blood loss or chronic disease, are excellent candidates for erythropoietin therapy.²⁶ Erythropoietin therapy was initiated regardless of the interval between evaluation and transplantation, although 2 weeks is the usual time when erythropoietin starts to show an effect.¹¹ Goodnough et al²⁷ have shown that preoperative erythropoietin can increase the amount of autologous blood in elective orthopedic procedures. Preoperative erythropoietin therapy and the limitation of phlebotomy for laboratory evaluation showed us that this was potentially a major area of improvement, not only in the Jehovah's Witnesses but in all candidates for liver transplantation. Intraoperatively, two other problems were solved. One was diminishing the loss of red blood cells; the other was correcting coagulopathy. The monitoring and the correction of coagulopathy were the most difficult of these problems. Plateletpheresis allowed us to conserve platelets. Several studies have shown a reduction in the need for blood transfusion, fresh frozen plasma, and platelet concentrates with the use of autologous, platelet-rich plasma in cardiac surgery.^{28–30} Our transfusions of autologous, platelet-rich plasma contained a mean platelet count of $4.5 \times 10^9/L$ for 300 to 400 mL. According to our blood bank, this amount is equal to 6 to 8 U from random donors. As can be seen in three of the four patients, the drop in the platelet count at the end of the procedure was minimal (Table 2). Again, this technique does not have to be limited to selected patients.

Intraoperative cell salvage has been used extensively in liver transplantation.^{5,6} Fortunately, the effect of cell salvage in our study patients was underestimated due to minimal bleeding, but the normovolemic hemodilution may have played an important role in minimizing the loss of red blood cells. The complications sustained by our patients are not uncommon in liver transplantation, yet their relationship to the blood conservation techniques used remains unclear.

In our current medical environment of managed care and ever increasing fiscal concerns, other factors to be considered are the charges generated by the use of blood products. Our study group showed a significant decrease in the total in-hospital charges from the charges of the comparison group. Other centers have studied the charges for cell salvage alone and found a savings of \$ 1800 per patient.⁶ Our results concur with this finding, and we believe that adding other blood conservation techniques does not add to the expense but rather enables the conservation of blood, which in turn results in the generation of fewer transfusion-related charges.

In conclusion, to perform liver transplantation on Jehovah's Witnesses, we were able to identify several existing techniques for blood conservation that could add a level of efficiency and safety to all liver transplantations, and we propose the use of these techniques whenever possible. Whether using these techniques and using less blood products is cost-effective will require further study, perhaps a randomized trial.

DISCUSSION

Ingemar Dawidson, MD, Dallas, Tex

The authors should be commended for being able to do liver transplants without blood transfusions. I assume that this included FFP and albumin. If one can do this in Jehovah's Witness patients without blood transfusions, shouldn't this be the goal in all liver transplants, and, if so, are you currently trying to do that in your routine liver transplants?

My second question is whether or not you have a protocol for intraoperative fluid therapy or replacement therapy in your routine liver transplants. If so, what are the principles? Do you use colloids? Who decides: you surgeons or the anesthesiologists? What would you do if the Jehovah's Witness patient bleeds out of control? How much would you actually save in terms of money per patient if you could transplant without blood transfusions? Please tell us how you resuscitate your clinical single-organ (liver) shock model.

Mohammed Atik, MD, Los Angeles, Calif

The feat to use no blood in three of their four selected liver transplants is indeed impressive; that they could do these complex operations with such a small amount of blood loss is even more remarkable. Obviously their accomplishment is principally due to their operative planning and skill. Credit should also be given to their avoidance of transfusion of stored blood and the peri-operative withdrawal and reinfusion of patients' own blood and platelets. There is evidence that multiple transfusion of stored blood and platelet dysfunction augment coagulopathy and bleeding tendencies. It is well known that an important limiting factor, besides hematocrit, for oxygen delivery and tissue perfusion, is the compensatory ability of the heart to increase cardiac output in the face of blood loss. In the absence of cardiovascular dysfunction, a hematocrit of around 35% is optimum in normovolemic patients. Most patients do well with a hematocrit of 30%, and those without cardiovascular and pulmonary disease can tolerate a hematocrit as low as 20% perioperatively, provided their plasma volume is maintained. These principles demonstrated by the authors are also applicable to other areas of surgery.

At UCLA, in 18 consecutive, elective reconstructive operations for aneurysm and occlusive disease, we have used half as much blood transfusions as in comparable operations reported by other well-respected medical centers (mean of 1.7 U vs 4–5 U of blood). More pertinent to this discussion, six of our patients (or in one third of our patients), no blood or platelets, autologous or otherwise, were used, with no ill effects. We could have done better if we did not have unavoidable blood loss (mean of 1060 ± 495 cc) due to use of porous prosthesis, flushing, and heparinization and if we did not deal with older patients (mean age of 64 ± 7 years) with considerable cardiovascular disease and limited cardiac compensatory mechanism to tolerate a low hematocrit. Our experience with these operations, all performed by residents under supervision, though not as spectacular as that of the authors, confirms their findings and demonstrates that complex operations, traditionally performed with several units of blood, can be performed safely with little or no blood transfusions.

Dr Ramos

First of all, Dr Dawidson, we were not allowed to use FFP in our patients, only albumin and hetastarch. That is why we included PT greater than 15 in the restrictive guidelines. We are presently undergoing plans for a randomized trial of cell salvage and these techniques in the average liver transplant. Unfortunately we have found a bit of resistance from several of our surgeons, but I think that we will be able to overcome this resistance.

The intraoperative management of fluids is managed by Anesthesia. Dr Kang is a world-class liver transplant anesthesiologist and has published extensively on both cell salvage and on resuscitation and coagulation in liver transplantation. He was the anesthesiologist of record in all of these cases.

The question is, what would we do if the patient starts bleeding uncontrollably? There is only one thing legally we could have done, and that is to pray. The rights of these patients are protected by legal precedent, and we are not allowed to transfuse an adult Jehovah's Witness. If we do, it is assault. Dr Roger Jenkins from Massachusetts has published a paper using cell salvage alone and found a \$ 1800 savings in orthotopic liver transplants in about 40 cases. He didn't transplant Jehovah's Witnesses, but his average blood utilization was approximately 35 U.

We optimize filling pressures by using 4–5 L of crystalloid. The isovolemic hemodilution takes place in actually every liver transplant because these patients have not eaten or drunk fluids for about 24 hours; when they come to the operating room, they are fairly dehydrated. Their hematocrits are high. If we optimize filling pressures with 2–4 L of either albumin or hetastarch or even crystalloid, we can obtain high oxygen transports in these patients who, by virtue of their portal hypertension, already have cardiac outputs that are increased to 8–10 L. We can obtain oxygen transports between 800 mL to 1000 mL per minute. The hematocrit of 35% was chosen arbitrarily by agreement between our departments.

The question about whether this should be used for every liver transplant is exactly why I wrote this paper. I have learned a lot from doing these patients. Unfortunately, since 1991, we haven't found one to fit our restrictive guidelines.

REFERENCES

1. Bontempo FA, Lewis JH, Van Thiel DH, et al. The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. *Transplantation* 1985;39:532–536. [PubMed: 3887694]

2. Goodnough LT, Wida Soegiarso R, Geha AS. Blood lost and blood transfused in coronary artery bypass graft operation as implications for blood transfusion and blood conservation strategies. *Surg Gynecol Obstet* 1993;177:345–351. [PubMed: 8211576]
3. Goodnough LT, Geha AS. A new era in blood conservation. *Ann Thorac Surg* 1991;51:703–704. [PubMed: 2025071]
4. Thurer RL, Lytle BW, Cosgrove DM, Loop FD. Autotransfusion following cardiac operations: a randomized prospective study. *Ann Thorac Surg* 1979;27:500–507. [PubMed: 454027]
5. Van Voorst SJ, Peters TG, Williams JW, Vera SR, Britt LG. Autotransfusion in hepatic transplantation. *Am Surg* 1985;51:623–626. [PubMed: 3904551]
6. Dzik WH, Jenkins R. Use of intraoperative blood salvage during orthotopic liver transplantation. *Arch Surg* 1985;120:946–948. [PubMed: 3893391]
7. Weber T, Marino IR, Kang YG, Esquivel CD, Starzl TE, Duquesnoy RJ. Intraoperative blood transfusions in highly alloimmunized patients undergoing orthotopic liver transplantation. *Transplantation* 1989;47:797–801. [PubMed: 2655216]
8. Brajtford D, Paulsen AW, Ramsay MAE, et al. Potential problems with autotransfusion during hepatic transplantation. *Transplant Proc* 1989;21:2347–2348. [PubMed: 2652762]
9. UNOS Board of Directors. Urgency Criteria Policy 3.6 (Allocation of Livers). United Network of Organ Sharing; Richmond Va: Mar. 1991
10. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in predialysis patients: a double-blind placebo-controlled trial. *Ann Intern Med* 1989;110:108–114. [PubMed: 2909202]
11. Fletcher JL, Perez JC, Jones DH. Successful use of subcutaneous recombinant human erythropoietin before cholecystectomy in an anemic patient with religious objections to transfusion therapy. *Am Surg* 1991;57:697–700. [PubMed: 1746777]
12. Lewis JH, Bontempo FA, Swad SA, et al. Liver transplantation: intraoperative changes in coagulation factors in 100 first transplants. *Hepatology* 1989;9:710–714. [PubMed: 2651269]
13. Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. *Anesth Analg* 1985;64:888–896. [PubMed: 3896028]
14. Gravlee GP. Autologous platelet-rich plasma in cardiac surgery: aesthetics versus virtue. *J Cardiothorac Vase Anesth* 1993;7:1–3.
15. Stehling L, Zauder HL. Acute normovolemic hemodilution. *Transfusion* 1991;31:857–868. [PubMed: 1755091]
16. Williamson DR, Taswell HF. Intraoperative blood salvage: a review. *Transfusion* 1991;31:662–675. [PubMed: 1891796]
17. Tzakis A, Todo S, Starzl TE. Orthotopic liver transplantation with preservation of the inferior vena cava. *Ann Surg* 1989;210:649–652. [PubMed: 2818033]
18. Kang YG, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. *Anesthesiology* 1987;66:766–773. [PubMed: 3296855]
19. Pugh RNH, Murray Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973;60:646–649. [PubMed: 4541913]
20. Jehovah's Witnesses and the Question of Blood. Watchtower Bible and Tract Society; Brooklyn, NY: 1977. p. 1-64.
21. Genesis 9:3–4.
22. Leviticus 17:11, 13–15.
23. Deuteronomy 12:23–25.
24. In re Estate of Brooks. 1965. p. 372-373. 32 III 2d 361 III App Ct, 1st Dist
25. Dixon JL, Smalley MG. Jehovah's Witnesses: the surgical/ethical challenge. *JAMA* 1981;246:2471–2472. [PubMed: 7299971]
26. Van Stone JC. Who should receive recombinant human erythropoietin? *Semin Nephrol* 1989;9(suppl 2):3–7. [PubMed: 2669084]

27. Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. *N Engl J Med* 1989;321:1163–1168. [PubMed: 2677725]
28. Harke H, Tanger D, Furst-Denzer S, et al. Effect of a preoperative separation of platelets on the postoperative blood loss subsequent to extracorporeal circulation in open heart surgery. *Anaesthesist* 1977;26:64–71. [PubMed: 842811]
29. Giordano GF, River SL, Chung GKT, et al. Autologous platelet-rich plasma in cardiac surgery: effect on intraoperative and postoperative transfusion requirements. *Ann Thorac Surg* 1988;46:416–419. [PubMed: 3178351]
30. Noon GP, Jones J, Fehir K, et al. Use of preoperatively obtained platelets and plasma in patients undergoing cardiopulmonary bypass. *J Clin Apheresis* 1990;5:91–96. [PubMed: 2298724]

Table 1

Characteristics of Study Patients

	Patient No.			
	1	2	3	4
Diagnosis	Postnecrotic cirrhosis	Primary biliary cirrhosis	Alpha ₁ -antitrypsin deficiency	Fulminant hepatic failure
UNOS priority status [*]	3	3	3	4
Age, y	58	46	19	13
Previous surgery	None	None	Central splenorenal shunt, cholecystectomy	None
Immediate indication for orthotopic liver transplantation	Variceal hemorrhage, encephalopathy	Encephalopathy, weakness, vertebral compression fractures	Encephalopathy	Fulminant failure
Albumin level, g/L	23	30	20	25
Bilirubin level, μ mol/L (mg/dL)	174.4 (10.2)	218.9 (12.8)	6.8 (0.4)	473.7 (27.7)
Ascites [†]	++	++	+++	++
Grade of encephalopathy [‡]	2	2	3	4

^{*} UNOS indicates United Network for Organ Sharing. See UNOS Board of Directors,⁹ 1991. for an explanation of UNOS priority status for transplantation.

[†] Two plus signs indicate requiring medical therapy; three plus signs, requiring aggressive diuretic therapy with large-volume paracentesis.

[‡] For encephalopathy grades, 2 indicates alert with diminished level of consciousness; 3, alternating stupor with agitation; and 4, coma.

Table 2

Analysis of Blood Conservation Therapy

Laboratory Values	Patient No.			
	1	2	3	4*
Hematocrit level				
At initial evaluation	0.26	0.30	0.32	0.25
At transplantation	0.40	0.39	0.45	0.23
Platelet count, $\times 10^9/L$				
At transplantation	269 000	204 000	255 000	NA
Following plateletpheresis	161 000	111 000	193 000	NA
Postoperatively	225 000	185 000	202 000	NA

* NA indicates not applicable.

Conversions From Système International (SI) Units to Conventional Units (Modified From *The SI Manual In Health Care*)

System *	Component	SI Reference Interval [†]	SI Unit [‡]	Conversion Factor (Divide by)	Conventional Reference Interval [†]	Conventional Unit
S	Albumin	40–60	g/L	10.0	4.0–6.0	g/dL
B	Hematocrit	0.33–0.43	1	0.01	33–43	%
		0.39–0.49	1	0.01	39–49	%
B	Thrombocytes (platelets)	150–450	10 ⁹ /L	1	150–450	10 ³ /cu mm

* B represents blood; S, serum.

[†] These reference values are not intended to be definitive since each laboratory determines its own values. They are provided for illustration only.

[‡] An arabic one in this column indicates that this item, formerly expressed in percent, should be expressed as a decimal (or the appropriate part of 1).